株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

象皮病(リンパ系フィラリア症):パイプライン分析

Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H2 2019

発行 Global Markets Direct 商品コード 302485
出版日 ページ情報 英文 30 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.53円で換算しております。
Back to Top
象皮病(リンパ系フィラリア症):パイプライン分析 Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H2 2019
出版日: 2019年08月30日 ページ情報: 英文 30 Pages
概要

象皮病(別名:リンパ系フィラリア症)は、フィラリア寄生虫が蚊により人体に媒介されることで発症します。通常は幼児期に感染し、リンパ系に隠れた損傷を与えます。糸状虫上科(family Filariodidea)の線虫(回虫)に分類される寄生虫への感染が、この疾患の主な発症要因となっています。主な症状として、腫れ物や悪寒戦慄、発汗、頭痛、嘔吐などが挙げられます。主な治療法には抗生物質などがあります。

当レポートでは、世界各国での象皮病(リンパ系フィラリア症)治療用のパイプライン製品の開発状況について分析し、パイプライン製品の開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査して、その結果をお届けします。

目次

イントロダクション

  • 分析範囲

象皮病の概要

治療薬の開発

  • 象皮病向けパイプライン製品:概要
  • 象皮病向けパイプライン製品:比較分析

各企業で開発中の象皮病治療薬

大学/研究機関で研究中の象皮病治療薬

パイプライン製品の概略

  • 初期段階の製品

象皮病治療薬:開発中の製品の一覧(企業別)

象皮病治療薬:研究中の製品の一覧(大学/研究機関別)

象皮病治療薬の開発に従事している企業

  • Johnson & Johnson
  • エーザイ
  • Anacor Pharmaceuticals, Inc.

象皮病:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 作用機序別
  • 分子の種類別

薬剤のプロファイル

  • フィラリア症ワクチン
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • フルベンダゾール
  • IIC-942A001
  • IIC-950A001
  • リンパ系フィラリア症向け小分子
  • S-0112091
  • S-0112094
  • 象皮病向け小分子
  • リンパ系フィラリア症向け小分子
  • リンパ系フィラリア症・糸状虫病向け小分子
  • 線虫病向け小分子

付録

図表一覧

図表

List of Tables

  • Number of Products under Development for Elephantiasis (Lymphatic Filariasis), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Elephantiasis (Lymphatic Filariasis) - Pipeline by AbbVie Inc, H2 2019
  • Elephantiasis (Lymphatic Filariasis) - Pipeline by Eisai Co Ltd, H2 2019
  • Elephantiasis (Lymphatic Filariasis) - Pipeline by Medicines Development Ltd, H2 2019
  • Elephantiasis (Lymphatic Filariasis) - Dormant Projects, H2 2019

List of Figures

  • Number of Products under Development for Elephantiasis (Lymphatic Filariasis), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
目次
Product Code: GMDHC11376IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H2 2019, provides an overview of the Elephantiasis (Lymphatic Filariasis) (Infectious Disease) pipeline landscape.

Elephantiasis commonly known as Lymphatic filariasis occurs when filarial parasites are transmitted to humans through mosquitoes. Infection is usually acquired in childhood causing hidden damage to the lymphatic system. Lymphatic filariasis is caused by infection with parasites classified as nematodes (roundworms) of the family Filariodidea. Symptoms include swelling, shaking chills, sweating, headaches, and vomiting. Treatment includes antibiotics.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Elephantiasis (Lymphatic Filariasis) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Elephantiasis (Lymphatic Filariasis) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Elephantiasis (Lymphatic Filariasis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Elephantiasis (Lymphatic Filariasis) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Elephantiasis (Lymphatic Filariasis) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Elephantiasis (Lymphatic Filariasis) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Elephantiasis (Lymphatic Filariasis) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Elephantiasis (Lymphatic Filariasis) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Elephantiasis (Lymphatic Filariasis) (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Elephantiasis (Lymphatic Filariasis) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Elephantiasis (Lymphatic Filariasis) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
  • Global Markets Direct Report Coverage
    • Elephantiasis (Lymphatic Filariasis) - Overview
    • Elephantiasis (Lymphatic Filariasis) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Elephantiasis (Lymphatic Filariasis) - Therapeutics Assessment
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Elephantiasis (Lymphatic Filariasis) - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • Eisai Co Ltd
    • Medicines Development Ltd
  • Elephantiasis (Lymphatic Filariasis) - Drug Profiles
    • ABBV-4083 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AWZ-1066S - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EDE-1206 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • filariasis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lymphatic filariasis (multivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lymphatic filariasis (multivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • moxidectin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Elephantiasis (Lymphatic Filariasis) - Dormant Projects
  • Elephantiasis (Lymphatic Filariasis) - Product Development Milestones
    • Featured News & Press Releases
      • Jan 08, 2019: New anti-Wolbachia drug with potential to treat onchocerciasis and lymphatic filariasis
      • Sep 14, 2018: £1.5M to develop candidate drug to treat onchocerciasis and lymphatic filariasis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top